MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
USA - NASDAQ:MDXG - US6024961012 - Common Stock
6.55 USD
+0.07 (+1.08%)
6.55 USD
0 (0%)
Overall MDXG gets a fundamental rating of 6 out of 10. We evaluated MDXG against 533 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make MDXG a good candidate for value investing.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
MDXG had a positive operating cash flow in the past year.
In multiple years MDXG reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 12.80%, MDXG belongs to the top of the industry, outperforming 94.75% of the companies in the same industry.
Looking at the Return On Equity, with a value of 17.09%, MDXG belongs to the top of the industry, outperforming 95.12% of the companies in the same industry.
The Return On Invested Capital of MDXG (15.15%) is better than 95.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 10.38%, MDXG belongs to the top of the industry, outperforming 92.12% of the companies in the same industry.
MDXG's Operating Margin of 13.73% is amongst the best of the industry. MDXG outperforms 92.87% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 81.99%, MDXG belongs to the top of the industry, outperforming 85.55% of the companies in the same industry.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
Compared to 5 years ago, MDXG has more shares outstanding
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
MDXG has an Altman-Z score of 9.54. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 9.54, MDXG belongs to the best of the industry, outperforming 83.11% of the companies in the same industry.
MDXG has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.27, MDXG belongs to the top of the industry, outperforming 95.31% of the companies in the same industry.
MDXG has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
MDXG has a worse Debt to Equity ratio (0.07) than 62.10% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 9.54 |
ROIC/WACC1.75
WACC8.67%
2.3 Liquidity
A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Current ratio (4.41) which is comparable to the rest of the industry.
A Quick Ratio of 3.95 indicates that MDXG has no problem at all paying its short term obligations.
MDXG's Quick ratio of 3.95 is in line compared to the rest of the industry. MDXG outperforms 48.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.71%.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
Based on estimates for the next years, MDXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.40% on average per year.
MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.54% yearly.
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y12.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.19 indicates a rather expensive valuation of MDXG.
Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 94.18% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.07. MDXG is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 19.17 indicates a rather expensive valuation of MDXG.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 93.62% of the companies in the same industry.
MDXG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.08, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.19 | ||
| Fwd PE | 19.17 |
4.2 Price Multiples
95.50% of the companies in the same industry are more expensive than MDXG, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaply inside the industry as 96.44% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.51 | ||
| EV/EBITDA | 12.31 |
4.3 Compensation for Growth
MDXG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MDXG may justify a higher PE ratio.
MDXG's earnings are expected to grow with 17.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y8.55%
EPS Next 3Y17.4%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.55
+0.07 (+1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change-0.71%
Ins Owners1.83%
Ins Owner Change0.25%
Market Cap969.14M
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (89.92%)
Short Float %3.08%
Short Ratio5.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)21.15%
EPS NQ rev (3m)27.27%
EPS NY rev (1m)30.77%
EPS NY rev (3m)68.32%
Revenue NQ rev (1m)1.39%
Revenue NQ rev (3m)1.68%
Revenue NY rev (1m)5.61%
Revenue NY rev (3m)8.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.19 | ||
| Fwd PE | 19.17 | ||
| P/S | 2.46 | ||
| P/FCF | 14.51 | ||
| P/OCF | 14.29 | ||
| P/B | 4.06 | ||
| P/tB | 4.65 | ||
| EV/EBITDA | 12.31 |
EPS(TTM)0.36
EY5.5%
EPS(NY)0.34
Fwd EY5.22%
FCF(TTM)0.45
FCFY6.89%
OCF(TTM)0.46
OCFY7%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.37
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 9.54 |
F-Score6
WACC8.67%
ROIC/WACC1.75
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y12.54%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year35.54%
EBIT Next 3Y15.54%
EBIT Next 5YN/A
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 18.19 and the Price/Book (PB) ratio is 4.06.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.